Pharmacoeconomic comparison of the second generation insulin analogs and insulins on their base
Open Access
- 24 April 2021
- journal article
- Published by Publishing House OKI in Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice
- Vol. 20 (1), 4-15
- https://doi.org/10.37489/2588-0519-2021-1-4-15
Abstract
Effective control of Diabetes Mellitus (DM) is an actual task from clinical and economic points of view. The second generation insulin analogs increase level of DM compensation without hypoglycemia. The economic aspects of their usage have been evaluated early, but it is still actual due to changes in prices and new data about clinical efficacy were published.Materials and methods: Clinical-economic comparison of insulin glargine 300 U/ml (iGla 300), insulin degludec (iDeg) and insulin degludec/ insulin aspart (iDegAsp) in the Russian conditions has been performed in naïve patients’ group as well as in the group of patients with previous insulintherapy. Number of patients with HbA1c Results: iGla 300 can give an economy till 20 % for medication cost and till 10 % for direct medical expenditures in compare with iDeg in DM Type 1. For both patients’ groups iGla 300 can save 10-23 % of sources in compare with iGed and iDegAsp in DM Type 2. In DM2T iGla 300 had more efficacy and less cost in compare with iDeg in elderly patients with renal insufficiency.Conclusion: An effective control of DM with modern insulins is profitable from government position of payment due to decreasing expenditures for complications treatment.Keywords
This publication has 21 references indexed in Scilit:
- Switching to Once-Daily Insulin Degludec/Insulin Aspart from Basal Insulin Improves Postprandial Glycemia in Patients with Type 2 Diabetes Mellitus: Randomized Controlled TrialDiabetes & Metabolism Journal, 2020
- Premix insulins in type 1 diabetes: the coming of degludec/aspartExpert Opinion on Drug Metabolism & Toxicology, 2019
- Global trends in diabetes complications: a review of current evidenceDiabetologia, 2018
- Comparative Benefits and Harms of Basal Insulin Analogues for Type 2 DiabetesAnnals of Internal Medicine, 2018
- Comparative pharmacoeconomic evaluation of the treatment of type 2 diabetes mellitus with insulin degludec and insulin glargine in basal-bolus insulin therapyProblemy Endokrinologii, 2017
- Economic evaluation of type 2 diabetes mellitus burden and its main cardiovascular complications in the Russian FederationDiabetes mellitus, 2016
- Insulin degludec: a new basal insulin analogue with an ultra-long duration of action. Safety and efficacy in Russian patients with diabetesDiabetes mellitus, 2015
- New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin‐naïve people with type 2 diabetes on oral glucose‐lowering drugs: a randomized controlled trial (EDITION 3)Diabetes, Obesity and Metabolism, 2015
- New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 2 Diabetes Using Oral Agents and Basal Insulin: Glucose Control and Hypoglycemia in a 6-Month Randomized Controlled Trial (EDITION 2)Diabetes Care, 2014
- New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 2 Diabetes Using Basal and Mealtime Insulin: Glucose Control and Hypoglycemia in a 6-Month Randomized Controlled Trial (EDITION 1)Diabetes Care, 2014